Aclaris Therapeutics entered into a Second Amended and Restated Sales Agreement with Leerink Partners LLC and Cantor Fitzgerald to offer and sell shares of common stock through at-the-market offerings. This agreement amends the previous facility dated February 27, 2025, which had a $100.0 million limit. The new arrangement allows sales at the Company's sole discretion based on market conditions and instructions regarding price or size limits. The Company will pay a commission of 3.0% of gross sales proceeds to the agents. Aclaris Therapeutics operates in the biopharmaceutical industry, developing treatments for inflammatory diseases.

Aclaris Therapeutics reported second quarter and six-month financial results for the period ended June 30, 2026. The company posted a net loss of $21.5 million ($0.15 per share) for the quarter and $41.3 million ($0.30 per share) year-to-date, compared to prior year losses of $15.4 million and $30.5 million respectively. Total revenue was $1.6 million for the quarter and $3.6 million for the six-month period, driven by royalties from license agreements with Lilly and Sun Pharma. Research and development expenses increased to $18.1 million for the quarter due to costs associated with ATI-052 and ATI-9494. As of June 30, 2026, cash and marketable securities totaled $170.6 million. Subsequent to quarter-end, Aclaris sold 7.3 million shares under its ATM agreement for $40.2 million in gross proceeds. The company reaffirmed timelines for Phase 1b results of ATI-052, a Phase 2 readout for bosakitug, and the initiation of Phase 2b trials for ATI-052 and modzatinib in late 2026. Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing novel product candidates for immuno-inflammatory diseases.